LISATA THERAPEUTICS, INC. quarterly report, Q1 FY2020

Filing summary

Period and entity: The supplied filing is Caladrius Biosciences, Inc.’s Form 10-Q for the quarter ended March 31, 2021, not a Lisata Therapeutics, Inc. filing or a 2020 Q1 filing as indicated in the request metadata. Figures below summarize the supplied filing.

Business context

Caladrius is a clinical-stage biopharmaceutical company developing autologous CD34+ cell therapies. Its pipeline includes CLBS16 for coronary microvascular dysfunction (CMD), HONEDRA (CLBS12) for critical limb ischemia, CLBS201 for diabetic kidney disease, and OLOGO (CLBS14) for refractory angina. The company reported no revenue for the quarter.

Financial results and liquidity

At March 31, 2021, cash and cash equivalents were $28.744 million and marketable securities were $82.767 million, totaling $111.511 million; working capital was approximately $109.6 million. Total liabilities were $4.593 million, including $0.536 million of operating lease liabilities; the filing reports no debt balance. Stockholders’ equity was $110.014 million. With no revenue, operating and profit margins are not meaningful.

Changes, financing, and outlook

• Operating expenses nearly doubled year over year: R&D rose 239%, primarily reflecting development activity across HONEDRA, CLBS16, and CLBS201; G&A increased 18%. Net loss increased from $4.0 million to $8.1 million.
• Operating cash use increased to $8.0 million. Investing activities used $65.1 million, mainly from net purchases of marketable securities; this largely reflects moving funds into investments rather than operating burn.
• Financing provided $85.3 million, principally from January and February 2021 equity-and-warrant offerings and warrant exercises. The company reported $85.5 million of net proceeds from issuance of common stock and warrants in its cash flow statement. The offerings substantially increased shares outstanding; warrants could create further dilution.
• Management stated that available cash was expected to fund operating expenses for at least 12 months after issuance of the financial statements, assuming an OLOGO Phase 3 study would not begin until agreement with the FDA on study design. The company also cautioned that further capital may be needed and may not be available on acceptable terms.
• Clinical outlook: the 105-patient CLBS16 FREEDOM Phase 2b trial had begun treating patients; a CLBS201 Phase 2 study was planned for the second half of 2021; and the company was seeking FDA agreement on an OLOGO Phase 3 design. HONEDRA enrollment in Japan remained delayed by COVID-19 restrictions and hospital capacity constraints, with timing uncertain.

Risks, contingencies, and other notable items

The company highlighted financing needs, clinical and regulatory uncertainty, patient-enrollment delays, and ongoing COVID-19 disruption. It reported no material changes to previously disclosed risk factors, no material legal proceedings or off-balance-sheet arrangements, and effective disclosure controls. It maintained a full valuation allowance against deferred tax assets; use of net operating losses may be limited by ownership-change rules. Marketable securities had $73,000 of gross unrealized losses at quarter-end.

Important facts to verify

• Confirm the intended issuer and period: the source is Caladrius Biosciences, Inc., Q1 2021.
• Review the reconciliation of the $85.5 million stock-and-warrant proceeds in the cash flow statement to the offering proceeds described in the notes.
• Assess cash runway against actual clinical-trial spending, potential OLOGO Phase 3 costs, and any future financing requirements.
• Evaluate dilution from the 2021 share issuances and outstanding warrants, including their exercise terms.
• Track COVID-19-related HONEDRA enrollment delays and the timing and regulatory milestones for the other programs.